ClinicalTrials.gg

LEO Pharma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 254 studies whose lead sponsor is LEO Pharma or one of 1 company grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare LEO Pharma with Jiangsu HengRui Medicine and Sino Biopharmaceutical →

Pipeline: 1 program

Each counted once: 1 with a study LEO Pharma leads registered in the last two years.

  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of LEO Pharma’s own registered studies; LEO Pharma’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs LEO Pharma’s studies test, most open studies first — 33 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 33; every drug is on its own page, and each page lists its sponsors.

Coming up

3 of LEO Pharma’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 1J
  9. J
  10. A
  11. 1S
  12. O
  13. 1N

Add all 3 to your calendar (.ics) → With an account.

All 254 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now52%Recruiting 4 · Enrolling by invitation 1
  • Under way, not recruiting1<1%
  • Completed23091%
  • Stopped early187%Terminated 15 · Withdrawn 3

Phase

  • Phase 181
  • Phase 274
  • Phase 359
  • Phase 415
  • Early Phase 11

Where

  • United States87
  • Germany76
  • France62
  • United Kingdom54
  • Canada51
  • Australia30

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 2515
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 126

By the year each study started; 27 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to LEO Pharma.

  • LEO Pharma
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    225 studies
  • Peplin
    Acquired — became part of LEO Pharma, Nov 11, 2009 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    29 studies →

Focus areas

Conditions LEO Pharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 254. Browse all 254 →